

Bone Metabolism Disorder in Epileptic Children

How to Cite This Article: Nakhaeymoghadam M, Teimouri A, Khaje A, hoseini SB. Bone Metabolism Disorder in Epileptic Children. Iran J Child Neurol. Spring 2018; 12(2): 17-24

MAaryam

NAKHAEYMOGHADAM MD¹,

Alireza TEIMOURI PHD¹,

Ali KHAJE MD¹,

Seyed BAHARE HOSEINI MSC¹

1.Children & Adolescent Health
Research Center, Resistant
Tuberculosis Institute, School of
Medicine, Zahedan University of
Medical Sciences, Zahedan, Iran.

Corresponding Author:
Teimouri A. PHD
Email: Alirezateimouri260@gmail.
com

Revised: 10- Feb -2016
Last Revised: 09- Mar-2016
Accepted: 07- Jun -2017

Abstract

Objective

There are frequent anti-epileptic drugs used in management of epilepsy. Anti-epileptic drugs may have some complications on bone and vitamin D metabolism. This study aimed to comparison the bone metabolism disorder in epileptic children with healthy child in Zahedan, eastern Iran from Jul 2014 to Jun 2015.

Materials & Methods

This case-control study was performed on bone metabolism disorder in epileptic children from 2014-2015. Forty epileptic children were enrolled based on accessibility scheme and 40 participants randomly selected for control group from those referred to the pediatric ward and clinic of Ali ibn Abi Talib Hospital and Ali Asghar Clinic in Zahedan City, Sistan & Baluchestan Province, eastern Iran. Blood samples were collected from all participants to assess serum calcium, phosphorus, PTH, magnesium, vitamin D, serum albumin, creatinine random urine.

Results

Of 40 epileptic children, 23 (57.5%) and 17 (42.5%) were male and female respectively. The prevalence of low vitamin D was 37.5% for patients compared to 12.5% for controls (chi-square=6.667 and P=0.010). Of 80 participants, 15 individuals had abnormal PTH level distributed of 2 and 13 for patients and control groups respectively (chi-square =9.928 and P=0.002). In the cases of Ca and Mg, their levels were similar in both patients and controls. The status of the parameters in the classification of normal and abnormal assessed based on number of medications intake resulted that number of medications intake had no effect on the status of the parameter.

Conclusion

The frequency of hyperparathyroidy and vitamin D deficiency increased in epileptic children.

Keywords: Anti-epileptic drugs; Bone metabolism; Epilepsy

Introduction

Epilepsy is one of major public health problems affecting nearly 50 million people worldwide. It is one of the most common and long-term neurological disorders with a prevalence of 4-10/1000 in developed countries. The prevalence is much higher in children and aged population (1-3). Epilepsy is defined more than two days epileptic seizure without any specific causes more than 24 h.

Patients with epilepsy are required long-term treatments and estimated that 1% of populations are taking medicine for epilepsy. Due to the long duration of treatment, these patients are at risk of side effects. Metabolic bone diseases and increased risk of fracture are the most important side effects for these patients. The relationship between antiepileptic drugs and the incidence of rickets, osteomalacia and increased fracture is reported (4, 5). The above-mentioned clinical or subclinical abnormalities are observed in 50% or more patients treated with antiepileptic drugs (6). Bone disorders due to antiepileptic drugs are affected by both duration and dose of these medicines and mostly are observed bone disorders with all antiepileptic medications except gabapentin for instance (7). Antiepileptic drugs are along with osteoporosis, other bone metabolism disorders and mineral materials such as hypocalcemia (8), hypophosphatemia (9), a decrease in the serum levels of vitamin D (10) and secondary hyperparathyroidism (11, 12). These biochemical changes are causes of being at decreasing bone density risk, osteoporosis and fracture for patients under medication (12). In addition, of mentioned factors along with drugs consumption reducing an amount of activities, sunlight exposure, vitamin D, and calcium have a strong role in bone disorders.

Bone disorders pathogenesis is multifactorial in these patients and including changes in the metabolism

of vitamin D, secondary hyperparathyroidism, direct inhibition of intestinal absorption of calcium, changes in the metabolism of vitamin K, reducing in calcitonin, motility, calcium, and exposure to sunlight, and production of endogenous estrogen (13). We study the relationship between bone metabolic disorders in children with epilepsy who were under long-term treatment and antiepileptic drugs.

Materials & Methods

This case-control study was conducted on 80 children with epilepsy diseases aged from 5 to 15 yr of which 40 were patients and 40 were controls to assess bone metabolism disorders. Sampling was random and easy access from those referred to the Pediatric Ward and clinics of Ali Ebn Abi Talib Hospital and Ali Asghar clinic in Zahedan City, Sistan & Baluchestan Province, Iran from Jul 2014 to Jun 2015.

The sample size of 80 was estimated based on $P_1=0.6\%$, $P_2=22\%$ and $Z_{1-\alpha/2} = 1.96$ with the desired precision of 5%, alpha of 0.05 (CI of 95%) and 80% of power. Sampling method for patients and controls was accessible means that referred patients to clinics or admitted to the pediatric ward entered to the case group. Patients had real exclusion criteria were excluded from the study. In addition, from those who were not taking antiepileptic drugs, 40 selected for the control group randomly. The control group participants were without any underline diseases and matched with patients based on age and sex.

Both case and control participants were in the normal range of weight, height, and growth. Blood samples were collected from all participants to assess the serum of calcium, phosphorus, PTH, magnesium, vitamin D, calcium urine, serum albumin, creatinine of random urine. Since these paraclinical tests are part of routine checkup for patients with epilepsy every six months, the researcher did not pay cost for

but for controls, they did.

Ethics Committees of Zahedan University of Medical Sciences approved the study for MD thesis coded of 1515. All parents, guardians, or legal representatives gave informed consent form before participating in the study.

All statistical analyses were performed using SPSS software, version 13.0 (Chicago, IL, USA). Age, weight, BMI, AED, and levels of calcium were expressed as the mean \pm standard deviation (SD) and frequency (percentage). Comparisons of the frequency distribution were conducted by chi-square test. A P-value <0.05 was considered statistically significant.

Results

Demographic of case and controls are presented in (Table 1). Between two groups of participants, the frequency of sex distribution was similar ($P > 0.05$). Mean age of participants was 7.95 ± 2.14 with the range of 5-15 yr. Patients had mean age of 8.17 ± 2.38 yr with maximum age of 13 yr and a minimum age of 5 yr. In healthy subjects, mean age was 7.73 ± 1.88 yr with maximum age of 12 yr and a minimum age of 5 yr. Means of age between healthy people and people with seizure did not show any different.

The prevalence of low vitamin D was 37.5% in patients compared to 12.5% in controls. (Chi-

Table 1. Sex distribution of study subjects in case and control

Sex	Control		Case		Total	
	n	%	n	%	n	%
Boys	23	57.5	20	50	43	53.75
Girls	17	42.5	20	50	37	46.25
Total	40	100	40	100	80	100

square=6.667 and $P=0.010$). From 80 participants, 15 individuals had abnormal PHT level distributed of 2(5%) and 13(32.50%) for control and patients participants respectively (chi-square=9.928 and $P=0.002$) (Table 2). In the cases of Ca and Mg, their levels were similar in both patients and control groups. For P and Ald all participants had normal

levels in both case and controls (Table 2). The status of the parameters in the classification of normal and abnormal assessed based on number of medicines intake. In all mentioned parameters, the number of medicines intake had no effect on the status of the parameter of normality in patients (Table 3).

Bone Metabolism Disorder in Epileptic Children

Table 2. The prevalence of vitamin D, calcium, phosphorus, albumin, magnesium hyper parathyroid groups

Variables	Status	Statistics	Participants		x ²	P-value
			Case	Control		
Vitamin D	Abnormal	N	15	5	6.667	0.010
		%	37.50%	12.50%		
	Normal	N	25	35		
		%	62.50%	87.50%		
	Total	N	40	40		
Parathyroid	Abnormal	N	13	2	9.928	0.002
		%	32.50%	5%		
	Normal	N	27	38		
		%	67.50%	95%		
	Total	N	40	40		
Calcium	Abnormal	N	3	1	10.53	0.305
		%	7.50%	2.50%		
	Normal	N	37	39		
		%	92.50%	97.50%		
	Total	N	40	40		
Magnesium	Abnormal	N	1	0	1.13	0.5
		%	2.50%	0		
	Normal	N	39	40		
		%	97.50%	100%		
	Total	N	40	40		
Phosphate	Abnormal	N	0	0	-	-
		%	0	0		
	Normal	N	40	40		
		%	100%	100%		
	Total	N	40	40		
Albumin	Abnormal	N	0	0	-	-
		%	0	0		
	Normal	N	40	40		
		%	100%	100%		
	Total	N	40	40		

Table 3. Chi-square test results to evaluate the effect of the drug on laboratory data only in patients

Variables	Status	No of medications consumption			Total	Chi- square	P-value
		1	2	3			
Vitamin D	Abnormal	4	7	4	15	1.068	0.586
	Normal	10	11	4	25		
	Total	14	18	8	40		
Parathyroid	Abnormal	2	7	4	13	3.569	0.168
	Normal	12	11	4	27		
	Total	14	18	8	40		
Calcium	Abnormal	1	1	1	3	0.389	0.823
	Normal	13	17	7	37		
	Total	14	18	8	40		
Magnesium	Abnormal	1	0	0	1	1.905	0.386
	Normal	13	18	8	39		
	Total	14	18	8	40		
Phosphate	Abnormal	0	0	0	0	-	-
	Normal	14	18	8	40		
	Total	14	18	8	40		
Albumin	Abnormal	0	0	0	0	-	-
	Normal	14	18	8	40		
	Total	14	18	8	40		

Discussion

Calcium and vitamin D play important roles in bone metabolism and preserving adequate bone mass. This study was performed on 80 children, of which 40 were taking antiepileptic drugs more than 6 months and 40 were healthy. Two groups were matched in age and sex.

Normal status of vitamin D has remarkable influence in children and adolescent who are growing. Our analysis showed that in the level of abnormality,

PTH and the level of serum calcium were higher in patients compared to controls.

Several factors have important role in calcium metabolism and bone disorder such as dark skin, contacts and lack of sufficient additional sunlight and supplementary vitamin D intake (14).

The effects of antiepileptic medicines on various exogenous and endogenous substances have been investigated. Some of antiepileptic drugs can cause vitamin D deficiency by influencing hepatic P450

Bone Metabolism Disorder in Epileptic Children

system in the liver or disrupt 25-hydroxylation liver.

Some antiepileptic drugs may have an association with metabolism and bone mineral cycles due to the effects on bone cells (osteoblasts and osteoclasts) (15, 16). Our study showed that the prevalence of vitamin D deficiency and hypoparathyroidism was higher in patients. In a study that performed on 33 patients treated with antiepileptic drugs, 36% had insufficient levels of vitamin D deficiency and 58% had low level (17). Another study conducted on 38 children who received antiepileptic drugs and 44 healthy, 75% of patients had vitamin D deficiency, and 21% had insufficient vitamin D levels and the amounts of PTH were different between patients and controls (18). Another study conducted on effects of anti-epileptic drugs on bone metabolism. The levels of serum calcium and serum phosphate were normal in 93.76%, 93.3% of patients' respectively. The ALP level was in the normal and higher than normal in 76.5% and 23.5% of patients respectively. The PTH levels were in the normal and higher than normal in 77.3% and 18.5% of patients. Increasing the level of alkaline phosphatase and PTH was significantly higher in patients than the control group (19). A similar study was conducted with the aims of assessing the effects of anticonvulsants on vitamin D metabolism in children with epilepsy, which 89 children with epilepsy and taking antiepileptic drugs for at least six months without underlying disease were included. About 42% of patients had vitamin D deficiency. Serum calcium and phosphate levels were in the normal range. Vitamin D levels were not statistically significant in some factors such as age group, sex, type of medicines for the treatment, therapy or Monotherapy Bridge and resistance to treatment (20). Similar to our results, in another study, the levels of vitamin D did not show differences accordance with the variables of age, sex, type of medication for the treatment, therapy or Monotherapy Bridge and of 111

patients, 22% were in the defence level of vitamin D and 41% had insufficient vitamin D (21). The results of this study were similar to our results.

In Conclusion, the frequency of hyperparathyroidy and vitamin D deficiency was higher in epileptic children. Supplemental vitamin-D administration in such patients may be helpful. Measuring calcium and vitamin D levels are essential in epileptic patients, especially when remembering that they are at higher risk of falling and bone fractures.

Acknowledgement

The authors would like to show their deep gratitude to all clinical staffs of the Ali ibn Abi Talib Hospital and Ali Asghar Clinic. No fund was received to conduct this study.

Author's Contribution

Nakhaei, Khaje carried out the experiment and design. Nakhaei supervised the project and Khajeh supported. Hosseini performed data collection and Teimouri involved with data analysis and writing the primary version of manuscript.

All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of interest

The authors strongly declare for any conflict of interests.

References

1. Scott RA, Lhatoo SD, Sander JW. The treatment of epilepsy in developing countries: where do we go from here? *Bull World Health Organ* 2001; 79(4):344-51.
2. Petty SJ, O'brien TJ, Wark JD. Anti-epileptic

- medication and bone health. *Osteoporosis Int* 2007; 18(2):129-42.
3. Kotsopoulos IA, Van Merode T, Kessels FG, De Krom MC, Knottnerus JA. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. *Epilepsia* 2002; 43(11):1402-9.
 4. Kruse R. Osteopathies in antiepileptic long-term therapy (preliminary report). *Monatsschrift für Kinderheilkunde* 1968;116(6):378-81.
 5. Schmid F. Osteopathien bei antiepileptischer Dauerbehandlung. *Fortschr Med* 1967; 85:381-2.
 6. Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. *Arch Neurol* 2001;58(9):1369-74.
 7. Gröber U, Kisters K. Influence of drugs on vitamin D and calcium metabolism. *Dermatoendocrinol* 2012; 4(2):158-66.
 8. Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. *Q J Med* 1986; 59(3):569-77.
 9. Bogliun G, Beghi E, Crespi V, Delodovici L, d'Amico P. Anticonvulsant drugs and bone metabolism. *Acta Neurol Scand* 1986;74(4):284-8. Hoikka V, Savolainen K, Esko M, Alhava EM. Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. *Acta Neurol Scand* 1981;64:122-131. Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, Spain W. Antiepileptic drug-induced bone loss in young male patients who have seizures. *Arch Neurol* 2002;59(5):781-6.
 10. Pack AM, Morrell MJ, Marcus R, Holloway L, Flaster E, Doñe S, Randall A, Seale C, Shane E. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. *Ann Neurol* 2005; 57(2):252-7.
 11. Petty SJ, Wilding H, Wark JD. Osteoporosis associated with epilepsy and the use of anti-epileptics—a review. *Current Osteoporosis Reports* 2016;14(2):54-65.
 12. Delucia MC, Mitnick ME, Carpenter TO. Nutritional rickets with normal circulating 25-hydroxyvitamin D: A call for re-examining the role of dietary calcium intake in north American infants. *J Clin Endocrinol Metab* 2003;88(8):3539-45.
 13. Song XQ, Wang ZP, Bao KR, Zhang JM, Wu J, Yan CH, Shen XM. Effect of carbamazepine and valproate on bone metabolism in children with epilepsy. *Chinese J Pediatr* 2005;43(10):728-32.
 14. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;2007(357):266-81.
 15. Murie J, Messow CM, Fitzpatrick B. Feasibility of screening for and treating vitamin D deficiency in forensic psychiatric inpatients. *J Forensic Leg Med* 2012 ;19(8):457-64.
 16. Nettekoven S, Ströhle A, Trunz B, Wolters M, Hoffmann S, Horn R, Steinert M, Brabant G, Lichtinghagen R, Welkoborsky HJ, Tuxhorn I. Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. *Eur J Pediatr* 2008;167(12):1369-77.
 17. Ashrafi MR, Khoshhal F, Rabani A, Salajegheh N, Nasab AM, Shams S, Ashtiani MH, Sotodeh A. Study of Antiepileptic Drugs effects on bone

Bone Metabolism Disorder in Epileptic Children

- metabolism. Iran J Pediatr 2005;15(4):347-52.
18. Zarrin Keyhani doost MD, Heshmat Moayyeri MD, Nahideh Khosroshahi MD, Rasool Molatefi MD. The evaluation of 25-hydroxy vitamin D, calcium, phosphate and alkaline phosphatase levels in epileptic children under antiepileptic medication. Tehran University Medical Journal 2011; 68(10): 590-594 .
19. Fong CY, Riney CJ. Vitamin D deficiency among children with epilepsy in South Queensland. J Child Neurol 2014;29(3):368-73.